**MRSA Testing and Treatment Protocol Version 3 1/7/15**

**MRSA Testing**

 ***Testing criteria for all patients at high risk for MRSA carriage including the following:***

* Patients with history of MRSA colonization or infection (such patients should be isolated initially pending surveillance testing results)
* Patients admitted to or transferred from ICU (unless already being treated with mupirocin)
* Patients with hospital or extended care facility admission in the previous 6 months
* Patients who are nursing home or extended care facility residents, or residents of other congregate living setting including jail, group home, assisted living
* Patients receiving dialysis
* Patients with a history of IV drug use
* New clinical MRSA culture (sputum, wound, urine, etc)
* Patients with skin or soft tissue infection at admission

 ***For patients meeting the above criteria***

 ***If it is anticipated that the patient may have surgery SELECT:***

 MRSA/MSSA by PCR: Bilateral Nares

 routine

 ***For all others meeting criteria SELECT:***

 MRSA by PCR: Bilateral Nares

 routine

**Isolation for MRSA**

Order contact isolation for patients with history of MRSA colonization or infection or positive MRSA PCR or culture

 Patient isolation

 Contact:

Verify with Infection Prevention (5196) prior to discontinuation of isolation:

When MRSA nares test is negative **AND** no other cultures are pending or have final results that are positive for MRSA

**OR**

When MRSA POST BACTROBAN CULTURE after mupirocin (BACTROBAN) treatment is negative **AND** no other cultures are pending or have final results that are positive for MRSA

**For positive screen results SELECT:**

 mupirocin (BACTROBAN) 2% nasal ointment

 0.5 gram in each nostril 2 times a day for 5 day = 10 total doses

**24 hours after last dose of mupirocin for MRSA positive patients SELECT:**

 MRSA POST BACTROBAN CULTURE

 routine 24 hours after last dose of mupirocin